The development of protein–polysaccharide conjugate vaccines has had a
major impact on Haemophilus influenzae type b disease.
The application of this technology to Neisseria
meningitidis is also striking, particularly for serogroup
C. However, significant challenges exist for the development
of vaccines against non-typeable H. influenzae
and against N. meningitidis serogroup B.
Issues such as
non-vaccine-strain replacement and correlates of protection
need to be addressed as well as the longer-term implications
of vaccination against what are essentially 'normal'
microflora.
Full
Text Access
